These studies suggest that responses to cytotoxic chemotherapy vary greatly in patients with NSCLC, and individualized therapy based on RRM1 expression may help improve the efficacy of chemotherapeutic agents [24]. This evidence concerns the gene RRM1 and non-small cell lung carcinoma.